Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as LY4065967 Tablet
LY4065967 · 3 trials · 4 indications
| Arm | Type | Description |
|---|---|---|
| LY4065967 | EXPERIMENTAL | LY4065967 administered orally. |
| Placebo | PLACEBO_COMPARATOR | Placebo administered orally. |
| Name | Type | Description |
|---|---|---|
| LY4065967 | DRUG | Administered orally. |
| Placebo | DRUG | Administered orally |
Inclusion Criteria: * Have a history of low back pain for at least 3 months located between the 12th thoracic vertebra and the lower gluteal folds, with or without radiation * Have a body mass index at screening of ≤40 kilograms per meter squared (kg/m²). * Have stable glycemic control as indicated...
Top 4 of 15 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Eli Lilly and Company | LLY | 4 | PHASE3 | Retatrutide, LY3016859, LY3556050, LY3526318, LY3857210 |
| Fortress Biotech, Inc. | FBIO | 1 | PHASE3 | Tramadol |
| Merck & Co., Inc. | MRK | 1 | PHASE2 | MK-6916 |
| Creative Medical Technology Holdings, Inc. | CELZ | 1 | PHASE1 | CELZ-201-DDT |
LY4065967 is an investigational small molecule developed by Eli Lilly and Company for the treatment of chronic pain. It is being studied in Phase 2 clinical trials across several pain conditions, including chronic low back pain, diabetic peripheral neuropathic pain, and knee osteoarthritis pain. It is not yet approved for any indication.
LY4065967 is being evaluated for chronic pain conditions, specifically chronic low back pain, diabetic peripheral neuropathic pain, and osteoarthritis of the knee. These are the indications under study in its ongoing Phase 2 clinical program. No approved use has been established for LY4065967.
LY4065967 is developed by Eli Lilly and Company, which trades on the New York Stock Exchange under the ticker LLY. Lilly is the sponsor of the ongoing Phase 2 clinical trials evaluating the drug in chronic pain indications.
LY4065967 is in Phase 2 clinical development. All of its ongoing trials are Phase 2 studies, and the drug remains investigational. It has not been approved by the FDA or any other regulatory authority for any indication.
LY4065967 is being studied in three recruiting Phase 2 trials: NCT07641517 in knee osteoarthritis pain, NCT07641504 in chronic low back pain, and NCT07285018 in diabetic peripheral neuropathic pain. Each trial is randomized, double-blind, and placebo-controlled, enrolling approximately 150 participants in the United States and Puerto Rico.
Yes. LY4065967 Tablet is an alternative name for LY4065967, referring to the same investigational small molecule developed by Eli Lilly and Company for chronic pain. Searches for either name refer to the same Phase 2 drug candidate.